Newronika Appoints Keith Carlton as CEO to Enhance Strategic Leadership

New Leadership at Newronika: Keith Carlton Takes the Helm

In a crucial step for its future, Newronika, a leader in adaptive deep brain stimulation technology (AlphaDBS™), has appointed Keith Carlton as its new Chief Executive Officer, effective immediately. This announcement signifies a pivotal moment for the company as it seeks to solidify its strategic leadership and expand its global footprint in the innovative landscape of neuromodulation technology.

Carlton brings to Newronika a wealth of experience from the medical device sector. Throughout his career, he has demonstrated an ability to drive innovation, foster strategic growth, and achieve operational excellence within high-stakes environments. This makes him uniquely qualified to guide Newronika during this critical phase of expansion.

Lorenzo Rossi, PhD, co-founder and CEO of Newronika, expressed enthusiasm about Carlton's appointment, stating, "We are honored to welcome Keith as our CEO. His strategic vision and proven track record in developing innovative medical technology enterprises will be vital in advancing the clinical validation and commercialization of AlphaDBS, our patented deep brain stimulation system. This innovative platform is designed to provide precision therapy that enhances symptom relief while minimizing side effects for Parkinson's disease patients, all while strengthening Newronika's global presence."

Carlton's leadership is anticipated to enhance the company's journey following significant recent achievements, including receiving the CE mark approval for AlphaDBS, the FDA IDE authorization, and successfully closing a €13.6 million Series B funding round. These milestones underscore Newronika's commitment to revolutionizing neuromodulation therapy on a global scale.

In addressing his new role, Carlton shared, "Joining Newronika at such a transformative time is a privilege. The company's pioneering deep brain stimulation technology has the potential to redefine standard care for Parkinson's disease and other neurological disorders. I look forward to collaborating with the board and our talented team to drive innovation, increase patient access, and create significant global impact, starting with the pivotal Phase III clinical trial launch in the U.S."

As the company ramps up its operations and enhances its leadership team, the appointment of Carlton positions Newronika for what is expected to be a fruitful journey ahead. This transition comes at a time when advancements in neuromodulation therapies are critically needed and offers a chance for Newronika to solidify its place as a frontrunner in the evolving landscape of medical technology.

Founded as a subsidiary of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and the University of Milan, Newronika is dedicated to transforming deep brain stimulation through adaptive technologies that utilize real-time neurophysiological feedback to optimize therapy. Headquartered in Milan, Italy, the company is advancing adaptive deep brain stimulation with regulatory approvals and clinical initiatives underway across Europe, the U.S., and other countries.